# 1921

> 1921 is a VC fund backing mHealth, Diabetes and Health Care. See 1 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Total investments: 1
- Last investment: Mar 2025
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/1921vc
- Website: https://www.1921.vc

1921 is a VC fund focused on mHealth and Diabetes. We invest in people who make type 1 diabetes suck less, in any which way, wherever they are.

## Contacts

5 contacts available for 1921. Shizune tracks 2 team members at 1921. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/1921?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| mHealth | 1 | 100% |
| Diabetes | 1 | 100% |
| Health Care | 1 | 100% |
| Personal Health | 1 | 100% |
| Machine Learning | 1 | 100% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Fredrik Debong | General Partner, CEO | 1 | — |
| Fredrik Debong | General Partner, CEO | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| OneTwenty | OneTwenty is an early-stage health tech start-up that develops multiple Machine Learning based solutions for people with diabetes as well as Medtech companies for sensor optimization, biomarker prediction, glucoregulatory models, and iAGC (interoperable automated glycemic controller). Our solution demonstrates unprecedented precision in bloodglucose prediction 120 minutes in advance. OneTwenty revolutionizes the life of people with Type 1 diabetes. |  | Seed | Mar 01, 2025 |  |

1 of 1 investments shown.

## Co-investors
- [DvH Ventures](https://shizune.co/investors/profile/dvh-ventures) — VC Fund, 1 deal together
- [Tiny Supercomputer Investment Company](https://shizune.co/investors/profile/tiny-vc) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does 1921 invest in?

1921 invests primarily in mHealth, Diabetes and Health Care startups, most often at Seed stage. Most of the 1 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact 1921?

Public channels for 1921 include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at 1921?

The team at 1921 includes Fredrik Debong (General Partner, CEO) and Fredrik Debong (General Partner, CEO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co